文献速递类风湿关节炎

类风湿关节炎一线TNF抑制剂与非TNF抑制剂生物制剂及靶向合成药物的疗效比较:美国大型注册研究结果

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
PubMed 文献 · Ann Rheum Dis · 2020-07-21

基于美国CORRONA类风湿关节炎注册研究,纳入≥18岁、CDAI>2.8且未使用过bDMARD/tsDMARD的RA患者,经倾向评分匹配后比较一线TNFi与非TNFi(bDMARDs/tsDMARDs)的1年疗效。结果显示除贫血发生率略 favoring TNFi组外,两组在CDAI、DAS28、患者报告结局等方面均无显著差异,未发现显著效应修饰因子。结论支持RA指南基于临床判断和患者偏好进行个体化治疗。

要点

  • 一线TNFi与非TNFi在RA患者1年疗效上无显著差异
  • 贫血发生率TNFi组略低(19.04 vs 24.01/100人年,p=0.03)
  • 未发现显著的治疗效应修饰因子

核心结论

  • 一线TNFi与非TNFi在RA患者1年疗效上无显著差异,支持指南推荐的个体化治疗。

研究设计与样本

  • 基于美国CORRONA类风湿关节炎注册研究,纳入≥18岁、确诊RA、基线CDAI>2.8且未使用过bDMARD或tsDMARD的患者,经倾向评分匹配比较一线TNFi与非TNFi的1年结局。

主要发现

  • 除贫血发生率外,TNFi与非TNFi组在CDAI、DAS28、患者报告结局(HAQ-DI、EQ-5D、睡眠、焦虑、晨僵、疲劳)等方面均无统计学显著差异。
  • 贫血发生率TNFi组为19.04/100人年,非TNFi组为24.01/100人年(p=0.03),略 favoring TNFi组。
  • 未发现任何潜在的效应修饰因子具有统计学显著性。

关键数值与推荐

  • 基线CDAI>2.8;年龄≥18岁;无既往bDMARD或tsDMARD使用。
  • TNFi包括阿达木单抗、依那西普、 certolizumab pegol、戈利木单抗、英夫利西单抗;非TNFi包括阿巴西普、托珠单抗、利妥昔单抗、阿那白滞素、托法替布。
  • 贫血发生率TNFi组19.04/100人年 vs 非TNFi组24.01/100人年,p=0.03。

临床怎么用

  • 一线选择TNFi或非TNFi生物制剂/靶向合成药物时,疗效证据不支持某一类优先,应基于临床判断和患者偏好个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) as the first-line treatment following conventional synthetic DMARDs, as well as potential modifiers of response, observed in US clinical practice. METHODS: Data were from a large US healthcare registry (Consortium of Rheumatology Researchers of North America Rheumatoid Arthritis Registry). The analysis included patients (aged ≥18 years) with a documented diagnosis of rheumatoid arthritis (RA), a valid baseline Clinical Disease Activity Index (CDAI) score of >2.8 and no prior bDMARD or tsDMARD use. Outcomes were captured at 1-year postinitiation of a TNFi (adalimumab, etanercept, certolizumab pegol, golimumab or infliximab) or a non-TNFi (abatacept, tocilizumab, rituximab, anakinra or tofacitinib) and included CDAI, 28-Joint Modified Disease Activity Score, patient-reported outcomes (including the Health Assessment Questionnaire Disability Index, EuroQol-5 Dimension score, sleep, anxiety, morning stiffness and fatigue) and rates of anaemia. Groups were propensity score-matched at baseline to account for potential confounding. RESULTS: There were no statistically significant differences observed between the TNFi and non-TNFi treatment groups for outcomes assessed, except the incidence rate ratio for anaemia, which slightly favoured the TNFi group (19.04 per 100 person-years) versus the non-TNFi group (24.01 per 100 person-years, p=0.03). No potential effect modifiers were found to be statistically significant. CONCLUSIONS: The findings of no significant differences in outcomes between first-line TNF versus first-line non-TNF groups support RA guidelines, which recommend individualised care based on clinical judgement and consideration of patient preferences.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2020. PMID: 32719038. doi:10.1136/annrheumdis-2020-217209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。